All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

ISB 2001 Shows Favorable Safety Profile and Antitumor Activity in R/R Multiple Myeloma

September 17th 2025

ISB 2001 had a manageable safety profile and induced deep, durable responses at active doses in patients with relapsed/refractory multiple myeloma.

Cevostamab Plus Pomalidomide/Dexamethasone Is Safe, Active in R/R Myeloma

September 17th 2025

The combination of cevostamab, pomalidomide, and dexamethasone was deemed safe with early efficacy signals in relapsed/refractory multiple myeloma.

New AACR Cancer Progress Report Spotlights Notable Gains, Ongoing Challenges in Research

September 17th 2025

AACR published its annual Cancer Progress Report, outlining advances in cancer treatment and areas for future improvement.

Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, Newly Diagnosed Myeloma

September 17th 2025

Early and promising efficacy was shown with elranatamab added to daratumumab/lenalidomide in transplant-ineligible, newly diagnosed multiple myeloma.

Retifanlimab Displaces Chemo Alone as the Frontline Standard of Care in SCAC

September 17th 2025

Retifanlimab is the first and only immunotherapy agent to receive an indication for the frontline treatment of patients with advanced SCAC.

Optune Lua Secures Japanese Approval for Advanced NSCLC

September 17th 2025

Optune Lua plus concurrent PD-1/PD-L1 inhibition has been approved in Japan for advanced non–small cell lung cancer after platinum-based chemotherapy.

FDA Approves 2 Denosumab Biosimilars in High Fracture Risk Populations, Including in Breast and Prostate Cancer

September 17th 2025

Two denosumab biosimilars received approval from the FDA for the purpose of increasing bone mass in individuals at high risk for fracture.

As Pesticides and Wildfires Rise, Kids with Cancer Need Resources

September 17th 2025

Exposure to pollutants, such as pesticides and whildfires, could decrease brain and behavioral function in children, particularly in childhood cancer survivors.

Histone Modification–Related Gene Signature Shows Prognostic Value in Multiple Myeloma

September 17th 2025

An HMR risk signature predicted outcomes in multiple myeloma, linked with genomic instability, immune microenvironment, and drug sensitivity.

Neoadjuvant Palbociclib Plus Endocrine Therapy Does Not Improve PEPI Scores in Resectable HR+ Breast Cancer

September 17th 2025

Neoadjuvant palbociclib plus endocrine therapy did not improve PEPI scores in operable hormone receptor–positive breast cancer.

KN026 NDA in Pretreated HER2+ Gastric or GEJ Cancer Accepted by NMPA for Review

September 17th 2025

The NDA seeking approval of KN026 plus chemotherapy in HER2-positive gastric or GEJ cancer has been accepted for review in China.

Osimertinib Plus Chemotherapy Expands Frontline Choices in EGFR+ NSCLC

September 16th 2025

In an OncLive Peer Exchange, a panel of lung cancer experts discussed updated data in EGFR-mutated NSCLC from WCLC 2025.

T-DXd Shows Real-World Efficacy in HER2+ and HER2-Low/Zero Breast Cancer Brain Metastases

September 16th 2025

T-DXd demonstrated durable systemic and intracranial responses in patients with HER2-positive, -low, and -zero breast cancer brain metastases.

10 years, 10,000 lives: Mayo Experts Highlight the Journey and Future of Proton Beam and Particle Therapy at Mayo Clinic

September 16th 2025

New technology and facility expansions at the Mayo Clinic will soon enable it to treat nearly 75% more patients each year with even more precise and effective therapies.

Ligufalimab Nets FDA Orphan Drug Designation in AML

September 16th 2025

Ligufalimab has been granted orphan drug designation by the FDA for the treatment of patients with AML.

FDA Grants Fast Track Designation to CRB-701 for Pretreated Recurrent or Metastatic HNSCC

September 16th 2025

The novel ADC CRB-701 was granted FDA fast track designation for the treatment of patients with recurrent or metastatic pretreated HNSCC.

Metformin Plus Letrozole and Abemaciclib Induces CRs in ER+ Recurrent Endometrial Cancer

September 16th 2025

The combination of metformin, letrozole, and abemaciclib was safe and active in patients with ER-positive recurrent endometrial cancer.

FDA Approval of Belzutifan Provides Needed Option in Pheochromocytoma or Paraganglioma

September 16th 2025

The FDA approval of belzutifan in patients with pheochromocytoma or paraganglioma is a testament to the power of drug discovery in rare tumor subsets.

Final CAPTIVATE Analysis Data Support Frontline Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL

September 16th 2025

Paolo Ghia, MD, PhD, details the final analysis of the phase 2 CAPTIVATE study evaluating frontline ibrutinib/venetoclax in patients with CLL.

Neoadjuvant Tislelizumab Plus Chemo Drives Responses in Locally Advanced Cervical Cancer

September 15th 2025

Neoadjuvant tislelizumab plus chemotherapy yielded responses in locally advanced cervical cancer.